If you or a loved one are being treated for advanced Parkinson’s disease, consider ND0612 clinical studies
ND0612-012 – BeyoND
A phase II, open label, clinical study in 120 patients with advanced PD who are treated with 4 or more doses of levodopa per day, and have at least 2 hours of “OFF” time a day. The objective is to evaluate the long term safety and tolerability of subcutaneous infusion of ND0612 in patients with advanced PD over a 12-month period. The primary end point will be the long term systemic and local safety and tolerability of ND0612 infusion.
For more details press here